Health at a Glance 2011
Hide / Show Abstract

Health at a Glance 2011

OECD Indicators

This sixth edition of Health at a Glance provides the latest comparable data on different aspects of the performance of health systems in OECD countries. It provides striking evidence of large variations across countries in the costs, activities and results of health systems. Key indicators provide information on health status, the determinants of health, health care activities and health expenditure and financing in OECD countries.   Each indicator in the book is presented in a user-friendly format, consisting of charts illustrating variations across countries and over time, brief descriptive analyses highlighting the major findings conveyed by the data, and a methodological box on the definition of the indicator and any limitations in data comparability.

Click to Access: 
    http://oecd.metastore.ingenta.com/content/health_glance-2011-en/index.html
  • WEB
Publication Date :
23 Nov 2011
DOI :
10.1787/health_glance-2011-en
 
Chapter
 

Pharmaceutical expenditure You or your institution have access to this content

Click to Access: 
    http://oecd.metastore.ingenta.com/content/health_glance-2011-en/07/04/index.html
  • WEB
  • http://oecd.metastore.ingenta.com/content/8111101ec063.pdf
  • PDF
  • http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/health-at-a-glance-2011/pharmaceutical-expenditure_health_glance-2011-63-en
  • READ
Author(s):
OECD
DOI :
10.1787/health_glance-2011-63-en

Hide / Show Abstract

Pharmaceuticals account for almost a fifth of all health spending on average across OECD countries. The increased consumption of pharmaceuticals due to the diffusion of new drugs and the ageing of populations (see Indicator 4.11 "Pharmaceutical consumption") has been a major factor contributing to increased pharmaceutical expenditure and thus overall heath expenditure (OECD, 2008c). However, the relationship between pharmaceutical spending and total health spending is a complex one, in that increased expenditure on pharmaceuticals to tackle diseases may reduce the need for costly hospitalisations and interventions now or in the future.
Also available in: French